Rajeev Sharma

TL;DR: A multidisciplinary Toxicity Management Working Group met for a full-day workshop to develop recommendations to standardize management of immune-related adverse events, and presents their consensus recommendations on managing toxicities associated with immune checkpoint inhibitor therapy.

TL;DR: In this paper, the authors presented evidence-and consensus-based guidelines for the management of immune-related adverse events (irAEs) during ICI treatment, which were developed by the Society for Immunotherapy of Cancer (SITC).

TL;DR: In this article, an elderly man in the seventh decade of life was brought to the hospital with worsening mental status, and blood tests revealed anaemia and thrombocytopenia with elevated lactate dehydrogenase and serum lactate levels.

TL;DR: The patient presented with exaggerated Warburg effect (hyper-Warburgism), evident by extreme glucose consumption, severe lactic acidosis, and large tumor burden on PET/CT, and Chemotherapy corrected these abnormalities rapidly, and must be instituted in a timely manner.

TL;DR: In this article , an unusual case of Graves' disease potentially cured due to destructive thyroiditis caused by inflammation due to immune checkpoint inhibitors (ICIs) is presented, which is more common with PD-1 inhibitors than cytotoxic T-lymphocyte-associated protein 4 (CTLA-4).